Abstract
Vein graft disease remains a vexing issue for both coronary and peripheral bypass procedures. In general, only 50% to 60% of saphenous vein grafts used for coronary artery bypass grafting are still patent at 10 years. Although antithrombotic and lipid-lowering strategies have improved these results, vein graft stenosis is more than an angiographic phenomenon. Importantly, patients with early and late failure of these grafts have higher rates of reintervention, rehospitalization, and death. Intimal hyperplasia and atherosclerosis is widely considered an inflammatory-mediated disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
